Babban gudunmawar mu shine cewa ci gaba-saki farfadowa yana haɗawa da fa'idodin chemotherapy da immunotherapy, kuma a karon farko, an haɗa su biyu kuma an yi amfani da su zuwa maganin intratumoral ta hanyar shiga tsakani. Yana haɗawa da jiyya na gida da na duniya, kuma yana haɓaka haɓakawa da lokacin aikin miyagun ƙwayoyi ta hanyar ci gaba da sakin magunguna a cikin ƙari, wanda ba wai kawai yana taka rawar anticancer na gida na magungunan chemotherapy ba, har ma yana yin la'akari da rawar da ke tattare da tsarin rigakafi, don haka yana samar da gazawar sauran hanyoyin kwantar da hankali, samar da sabbin dabaru da hanyoyin magance cutar kansa, musamman ga ciwace-ciwacen ciwace da ci gaba, musamman don rage ƙimar ciwace-ciwacen ƙwayar cuta. Maganin UMPIC yana da fa'idar yin amfani da ƙari azaman tushen antigen da rigakafin autologous, wanda kuma yayi daidai da yanayin haɓakar Magungunan Keɓaɓɓen. Kuma amfani da asibitin, hapten hade da chemotherapy kwayoyi don ci gaba da saki jiyya na pancreatic ciwon daji na farko mayar da hankali, yayin da inducing distal sakamako, jigon wanda shi ne ya haifar da rigakafi da martani, T-cell CD4, CD8, DC, T da kuma NK Kwayoyin, da kuma B-cell da alaka da ƙari autoantibodies: Antibodies zuwa P53, P16, C16, Survival, P53, P16, Survival, P16, P16, P53, P16, P16, P53, P16, Survivin, P53. p62, HCC1 da sauran oncogenes, wannan shi ne karo na farko da aka gano cewa T da B suna da hannu a cikin rigakafi da amsa, da kuma asibiti ayyuka na distal sakamako da kuma wannan far da aka zaba domin "Clinical Operation Guidelines for Interventional Jiyya na Advanced Pancreatic Ciwon daji" (Trial) (7th edition) hadin gwiwa tsara ta kasar Sin Anti-Cancer Association da National Clinical Research Association da National Clinical Medical Association. Medicine Innovation Alliance aka buga a

Jaridar Clinical Radiology, juzu'i na 43, lamba 19, 2024, 1636-1648.